The HCC Virtual Experts Knowledge share will address “Appropriate selection of patients for 1st line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs”. Chaired by Prof. Richard Finn, MD, (USA) and co-chaired by Dr Mohamed Bouattour (France) and James Harding, MD (USA).
The educational objectives for the meeting are:
- Explore the patient-profile who could benefit from VEGFR-TKI monotherapy 1st line in advanced or unresectable HCC
- Interpret the real-world data and understand the implications for clinical practice
- Understand the safety profile of the monotherapies, be able to recognise the cause of toxicities and know the appropriate dosing strategies to manage side effects
- A look into the future, the potential of combination therapies in the treatment of HCC